West Virginia Pharmacy Services



Drug Utilization Review (DUR)

1st Quarter 2015

Prepared by:



West Virginia Department of Health and Human Resources Bureau for Medical Services

DUR QUARTERLY OVERALL SUMMARY REPORT FOR THE PERIOD 01/01/2015 THROUGH 03/31/2015

Categories	1st Qtr 2015	1st Qtr 2014	% Change
Total Paid Amount	\$107,849,996.74	\$78,815,902.17	36.84
Eligible Members	256,467	201,127	27.51
Utilizing Eligibles	165,888	120,484	37.68
Total # Prescriptions	1,806,653	1,363,874	32.46
Cost per Utilizing Member	\$650.14	\$654.16	-0.62
Average # Prescriptions per Utilizer	10.00	11.00	-9.09
Average Cost per Prescription	\$59.70	\$57.79	3.30
# Generic Prescriptions	1,566,799	1,155,054	35.65
% Generic Prescriptions	86.00	84.00	2.38
Total Cost - Generics	\$28,605,148.79	\$19,940,069.32	43.46
Average Generic Prescription Cost	\$18.26	\$17.26	5.76
Average Days Supply - Generics	25.00	25.00	0.00
# Brand Prescriptions	239,854	208,820	14.86
% Brand Prescriptions	13.00	15.00	-13.33
Total Cost - Brand	\$79,244,847.95	\$58,875,832.85	34.60
Average Brand Prescription Cost	\$330.39	\$281.95	17.18
Average Days Supply - Brand	25.00	26.00	-3.85
Rebates Collected	\$34,427,134.15	\$47,154,991.24	-26.99


Drug Utilization Review Board Meeting

Top 25 Therapeutic Classes By Prescription Count

Reporting Months (1st Quarter): 01/01/2015 - 03/31/2015

Rank	Therapeutic Class	Therapeutic Class Code	Prescription Count	% of Total Prescription Count	Amount Paid
1	ANTICONVULSANTS	H4B	126,662	6.90	\$6,085,421.47
2	ANALGESICS, NARCOTICS	НЗА	102,706	5.60	\$3,181,233.82
3	PROTON-PUMP INHIBITORS	D4J	79,020	4.30	\$2,626,994.59
4	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	H2S	71,432	3.90	\$576,760.35
5	ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	M4D	65,309	3.60	\$1,530,561.17
6	NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE	S2B	60,837	3.30	\$622,344.64
7	ANTI-ANXIETY DRUGS	H2F	59,821	3.30	\$480,595.57
8	ANTIHYPERTENSIVES, ACE INHIBITORS	A4D	48,842	2.70	\$307,899.80
9	BETA-ADRENERGIC BLOCKING AGENTS	J7C	47,914	2.60	\$711,198.71
10	BETA-ADRENERGIC AGENTS	J5D	44,390	2.40	\$2,157,002.88
11	ANTIHISTAMINES - 2ND GENERATION	Z2Q	40,383	2.20	\$284,232.09
12	SKELETAL MUSCLE RELAXANTS	н6н	37,689	2.10	\$440,080.70
13	THYROID HORMONES	P3A	35,375	1.90	\$513,163.34
14	ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,& SEROTONIN ANTAG	н7Т	32,386	1.80	\$3,957,408.37
15	ANTIHYPERGLYCEMIC, BIGUANIDE TYPE	C4L	30,563	1.70	\$357,375.74
16	PENICILLINS	W1A	29,644	1.60	\$433,165.56
17	VITAMIN D PREPARATIONS	C6D	27,906	1.50	\$185,151.93
18	ANTIHISTAMINES - 1ST GENERATION	Z2P	26,353	1.40	\$279,131.33
19	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	Н7С	26,162	1.40	\$1,164,256.48
20	INSULINS	C4G	25,689	1.40	\$11,656,633.57
21	GLUCOCORTICOIDS	P5A	24,812	1.40	\$520,225.69
22	CALCIUM CHANNEL BLOCKING AGENTS	A9A	24,114	1.30	\$261,710.42
23	HISTAMINE H2-RECEPTOR INHIBITORS	Z2D	21,437	1.20	\$177,114.18
24	THIAZIDE AND RELATED DIURETICS	R1F	20,677	1.10	\$141,901.52
25	LEUKOTRIENE RECEPTOR ANTAGONISTS	Z4B	20,277	1.10	\$470,646.86
	Totals:		1,130,400	61.70	\$39,122,210.78

Drug Utilization Review Board Meeting




Amount Paid	
ANTICONVULSANTS	\$6,085,421.47
ANALGESICS, NARCOTICS	\$3,181,233.82
PROTON-PUMP INHIBITORS	\$2,626,994.59
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	\$576,760.35
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	\$1,530,561.17
NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE	\$622,344.64
ANTI-ANXIETY DRUGS	\$480,595.57
ANTIHYPERTENSIVES, ACE INHIBITORS	\$307,899.80
BETA-ADRENERGIC BLOCKING AGENTS	\$711,198.71
BETA-ADRENERGIC AGENTS	\$2,157,002.88
ANTIHISTAMINES - 2ND GENERATION	\$284,232.09
SKELETAL MUSCLE RELAXANTS	\$440,080.70

Top 25 Therapeutic Classes by Amount Paid

Reporting Months (1st Quarter): 01/01/2015 - 03/31/2015

	Therapeutic Class	Therapeutic Class Code	Amount Paid	% of Total Amount Paid	Prescription Count
1	INSULINS	C4G	\$11,656,633.57	10.80	25,689
2	ANTICONVULSANTS	н4В	\$6,085,421.47	5.60	126,662
3	BETA-ADRENERGIC AND GLUCOCORTICOID COMBINATIONS	J5G	\$5,448,796.54	5.00	19,313
4	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	нтх	\$5,235,888.43	4.80	6,081
5	ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	Н7Т	\$3,957,408.37	3.70	32,386
6	ANALGESICS, NARCOTICS	нза	\$3,181,233.82	2.90	102,706
7	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	S2J	\$2,886,479.76	2.70	940
8	GENERAL BRONCHODILATOR AGENTS	A1D	\$2,878,620.90	2.70	10,785
9	PROTON-PUMP INHIBITORS	D4J	\$2,626,994.59	2.40	79,020
10	AGENTS TO TREAT MULTIPLE SCLEROSIS	HOE	\$2,336,722.59	2.20	457
11	BETA-ADRENERGIC AGENTS	J5D	\$2,157,002.88	2.00	44,390
12	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	\$2,108,754.13	2.00	13,747
13	NARCOTIC WITHDRAWAL THERAPY AGENTS	нзм	\$2,001,487.35	1.90	17,238
14	ANTISERA	W7K	\$1,677,761.00	1.60	368
15	LIPOTROPICS	M4E	\$1,609,659.50	1.50	15,172
16	ANTIHYPERGLYCEMIC, DPP-4 INHIBITORS	C43	\$1,602,143.24	1.50	5,125
17	ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	M4D	\$1,530,561.17	1.40	65,309
18	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	H2V	\$1,511,127.78	1.40	9,760
19	HEP C VIRUS - NS5B POLYMERASE & NS5A INHIB. COMBO.	WOB	\$1,317,342.00	1.20	42
20	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	V1Q	\$1,313,445.34	1.20	157
21	NASAL ANTI-INFLAMMATORY STEROIDS	Q7P	\$1,232,512.91	1.10	19,947
22	BLOOD SUGAR DIAGNOSTICS	M4A	\$1,210,513.03	1.10	19,151
23	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	H7C	\$1,164,256.48	1.10	26,162
24	ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANTAGONIST	A4F	\$901,790.88	0.80	13,393
25	ANTIVIRALS, GENERAL	W5A	\$838,390.70	0.80	10,010
	Totals:		\$68,470,948.43	63.40	664,010



Prescriptions	
INSULINS	25,689
ANTICONVULSANTS	126,662
BETA-ADRENERGIC AND GLUCOCORTICOID COMBINATIONS	19,313
ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	6,081
ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	32,386
ANALGESICS, NARCOTICS	102,706
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	940
GENERAL BRONCHODILATOR AGENTS	10,785
PROTON-PUMP INHIBITORS	79,020
AGENTS TO TREAT MULTIPLE SCLEROSIS	457
BETA-ADRENERGIC AGENTS	44,390
ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	13,747

Drug Utilization Review Board Meeting


4/22/2015

Generic Utilization Summary by Amount Paid **BNG BWG GEN** BNG \$68,149,762 63.1% BWG \$11,108,121 10.3% GEN \$28,776,884 26.6% \$108,034,767 100.0% Total:


BNG = Brand With no Generic Available BWG = Brand Dispensed when Generic Available GEN=Generic

Drug Utilization Review Board Meeting

04/22/2015



BNG = Brand With no Generic Available BWG = Brand Dispensed when Generic Available GEN=Generic



Code	Description	Amount Saved	% of Savings
DD	Drug-Drug Interactions	\$230,834.91	2.00
ER	Early Refill	\$9,140,160.89	61.00
HD	High Dose	\$630,940.84	4.00
ID	Ingredient Duplication	\$510,837.89	3.00
LR	Late Refill	\$0.00	0.00
PG	Pregnancy Precaution	\$66,190.07	0.00
TD	Therapeutic Duplication	\$4,448,435.43	30.00
	Totals:	\$15,027,400.04	100.00